drugset / Trial / NCT07234773
A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT501 administered subcutaneously to participants with Rheumatoid Arthritis (RA).
Timeline
- Start
- 2026-03-06
- Primary completion
- 2027-02
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KT501 | Monoclonal antibody | — | Subcutaneous |